Astrazeneca plc ADR (AZN) Stock Could Soon Reward Patient Investors

Astrazeneca plc ADR (NASDAQ: AZN) is -7.56% lower on its value in year-to-date trading and has touched a low of $61.70 and a high of $76.56 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The AZN stock was last observed hovering at around $63.52 in the last trading session, with the day’s loss setting it -1.26%.

Currently trading at $62.26, the stock is -6.77% and -6.14% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 13.73 million and changing -1.98% at the moment leaves the stock -8.94% off its SMA200. AZN registered -3.26% loss for a year compared to 6-month loss of -11.49%. The firm has a 50-day simple moving average (SMA 50) of $4.66 and a 200-day simple moving average (SMA200) of $15.35.

Invest Like Buffett: Travel Back in Time & Grab This High-Potential Stock Before It Explodes

Imagine buying Apple for $1, Amazon for $2, or Tesla for $3. Now, imagine the same opportunity with a hidden gem trading under $3 right now.

Our premium newsletter, powered by AI and expert analysis, uncovers these time-travel investment opportunities.

Invest like Buffett and profit from undervalued gems before the market catches on.

Limited-time offer: Get your first month for just $2.90 and start your journey to wealth creation.


The stock witnessed a -10.51% gain in the last 1 month and extending the period to 3 months gives it a -2.00%, and is -5.15% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 1.90% over the week and 1.33% over the month.

Astrazeneca plc ADR (AZN) has around Aug 10 2023 employees, a market worth around $193.03B and $45.81B in sales. Current P/E ratio is 32.58 and Fwd P/E is 13.29. Profit margin for the company is 13.00%. Distance from 52-week low is 0.91% and -18.68% from its 52-week high. The company has generated returns on investments over the last 12 months (9.55%).

Astrazeneca plc ADR quarterly earnings per share for the current quarter are estimated at $0.9 with sales reaching $11.83B over the same period.The EPS is expected to grow by 13.48% this year, but quarterly earnings will post 10.70% year-over-year. Quarterly sales are estimated to grow 12.10% in year-over-year returns.

Astrazeneca plc ADR (AZN) Top Institutional Holders

1,316 institutions hold shares in Astrazeneca plc ADR (AZN), with institutional investors hold 16.93% of the company’s shares. The shares outstanding are 3.10B, and float is at 3.10B with Short Float at 0.13%. Institutions hold 16.93% of the Float.

The top institutional shareholder in the company is Price (T.Rowe) Associates Inc with over 52.85 million shares valued at $3.78 billion. The investor’s holdings represent 2.01% of the AZN Shares outstanding. As of Jun 29, 2023, the second largest holder is Wellington Management Group, LLP with 49.13 million shares valued at $3.52 billion to account for 1.87% of the shares outstanding. The other top investors are Primecap Management Company which holds 44.08 million shares representing 1.68% and valued at over $3.15 billion, while Capital International Investors holds 1.46% of the shares totaling 38.34 million with a market value of $2.74 billion.

Astrazeneca plc ADR (AZN): Who are the competitors?

The company’s main competitors (and peers) include Eli Lilly & Co. (LLY) that is trading 111.23% up over the past 12 months. Biogen Inc. (BIIB) that is -17.04% lower over the same period.